CECXG (3'-ethyl-LY-341,495) is a research drug which acts as a potent and selective antagonist for the group II metabotropic glutamate receptors ( mGluR_2/3), with reasonable selectivity for mGluR₃. While it is some five times less potent than

LY-341,495 LY-341495 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as a potent and selective orthosteric antagonist for the group II metabotropic glutamate receptors ( mGluR2/3). It is used in scientific research in sever ...

at mGluR₃, it has 38x higher affinity for mGluR₃ over mGluR₂, making it one of the few ligands available that is able to distinguish between these two closely related receptor subtypes.

References

Drugs developed by Eli Lilly and Company Xanthenes MGlu2 receptor antagonists MGlu3 receptor antagonists {{nervous-system-drug-stub